Described herein is pyrrolo{2,3- d }pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof wherein R 1 is C 1-4 alkyl optionally substituted with hydroxy.
2. A compound of claim 1 wherein R 1 is methyl.
3. A compound of claim 1 wherein R 1 is ethyl, or cyclobutyl.
4. A compound of claim 1 which is N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide, or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
6. A crystalline Form A of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt.
7. The crystalline Form A of N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt according to claim 6 , which comprises an X-ray powder diffraction pattern having at least one characteristic peak expressed in degrees 2-theta at approximately 6.2, 12.6 and 15.7.
8. A process for preparing N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt Form A comprising reacting N-methyl-1-{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide with maleic acid.